Alvimopan (monohydrate)

Alvimopan monohydrate (ADL 8-2698 monohydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan monohydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively) . Alvimopan monohydrate can be used for the research of postoperative ileus[1][2][3].

Product Specifications

CAS Number

[1383577-62-5]

Product Name Alternative

ADL 8-2698 monohydrate; LY 246736 monohydrate

UNSPSC

12352005

Target

Opioid Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/alvimopan-monohydrate.html

Purity

99.18

Solubility

10 mM in DMSO

Smiles

OC1=CC=CC([C@@]2(C)[C@@H](C)CN(C[C@H](CC3=CC=CC=C3)C(NCC(O)=O)=O)CC2)=C1.O

Molecular Formula

C25H34N2O5

Molecular Weight

442.55

References & Citations

[1]Bourdonnec BL, et, al. Novel trans-3,4-dimethyl-4- (3-hydroxyphenyl) piperidines as mu opioid receptor antagonists with improved opioid receptor selectivity profiles. Bioorg Med Chem Lett. 2008 Mar 15;18 (6) :2006-12.|[2]Erowele GI, et, al. Alvimopan (Entereg), a Peripherally Acting mu-Opioid Receptor Antagonist For Postoperative Ileus. P T. 2008 Oct;33 (10) :574-83.|[3]Meerveld BG, et, al. Preclinical studies of opioids and opioid antagonists on gastrointestinal function. Neurogastroenterol Motil. 2004 Oct;16 Suppl 2:46-53.